We're thrilled to announce the official opening of TriApex Laboratories Inc., our state-of-the-art bioanalytical laboratory in Philadelphia, Pennsylvania! This milestone, which took place recently, marks a significant advancement in our bioanalytical service capabilities and strengthens our commitment to supporting the global development of innovative therapeutics.

TriApex US Lab is equipped with three main technical platforms to offer concentration analysis and immunogenicity evaluation services for bio-therapeutic products. Our services span early-phase research, nonclinical studies, and clinical trials, including cell and gene level analysis, immunoassays, and biomarker studies.

With the support of our group company's extensive resources, TriApex US Lab is well-positioned to provide additional services to our U.S. clients. These include bioanalytical services, collaborate on analytical method development and validation, and assistance with non-clinical and clinical research. Furthermore, we also facilitate connections between our U.S. clients and TriApex's global network, ensuring seamless coordination across international teams.

TriApex Group's Bioanalytical Experience Across the Drug Development Lifecycle

TriApex Group offers a comprehensive suite of Full Life Cycle Bioanalysis services, spanning from the discovery phase to IND, NDA, and clinical stages. Our expertise includes preclinical pharmacokinetics, bioanalysis across multiple platforms (LC-MS/MS, LBA, and PCR), translational medicine, immunogenicity analysis, and clinical pharmacology. We also provide central laboratory services and support in the development of laboratory manuals and clinical sampling kits.

We would like to express the heartfelt gratitude to our talented team and valued partners, who have played an integral role in bringing this vision to life.

We are eager to welcome collaborators, clients, and stakeholders to visit our new U.S. laboratory for discussions and potential partnerships. Together, we can drive innovation and make a meaningful impact on the drug development industry.